Begin Your Search

If you know the name of a drug manufacturer, you can easily search using the alphabetical menu below. Or you can search in free text – simply type the disease, drug, company name, or other detail into the Search bar below and click on the magnifying glass. For broadest results, type the terms without quotation marks; to narrow your search to an exact match, put your terms in quotation marks (i.e.; “breast cancer”). See Search Tips for tips and definitions to make your searches more effective.

The web links in this directory are public information provided to the Foundation and the acknowledgement times listed are the number of days or hours for a company to acknowledge receipt of request, not to make a decision. Data contained in this directory is provided either directly by the company or by ClinicalTrials.gov for the companies listed in this directory.

The Expanded Access listings provided on this website are limited to those companies currently in the Company Directory and include listings for expanded access which are Available, Temporarily Not Available and Approved for Marketing, which in some cases includes treatments which have not yet reached the market. In addition, many companies are willing to consider expanded access requests even if they do not show active Expanded Access Listings in this directory. Contact the company to explore the possibility of individual access to an investigational therapy.

To learn more about clinical trials and expanded access, please visit our patient and physician guides on this website.

4 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Company Name
Phone Number & Email
Company Acknowledgement

xCures Inc.

EA Webpage Clinicaltrials.gov
Phone Number & Email
Expected Application Timeframe
2 business days

Expanded Access to Gallium Maltolate (GaM)

Conditions
Glioblastoma
Refractory Glioblastoma
Glioblastoma Multiforme

The objective of this program is to provide GaM for compassionate use in patients withrelapsed/refractory histologic or molecular glioblastoma who have exhausted availabletreatments.The population of this program is adult patients aged greater than or equal to 18 yearswith a diagnosis of relapsed/refractory histologic or molecular glioblastoma, accordingto the WHO 2021 diagnostic criteria.Molecular glioblastoma is characterized as an IDH-wildtype diffuse and astrocytic gliomain adults if there is microvascular proliferation or necrosis or TERT promoter mutationor EGFR gene amplification or +7/-10 chromosome copy number changes

Disease/Category-Specific EA Policies/Criteria

https://enroll.xcures.com/static/ManagedAccessPolicy.pdf

Xynomic Pharmaceuticals, Inc.

EA Webpage Clinicaltrials.gov
Phone Number & Email
Expected Application Timeframe
5 business days
Single-Patient EA Policies/Criteria

Xynomic Pharmaceuticas, Inc. (Xynomic) is dedicated to developing new therapies that have a positive impact on patient health, and to serving patients, patient families and patient communities through education, empathy, and awareness.
Xynomic development resources are focused on conducting clinical studies required by regulatory authorities to fully answer important scientific questions about the potential risks and benefits of our investigational products, and to obtain regulatory approval.
Xynomic is committed to making investigational products available to seriously ill patients who have exhausted other treatment options. A treating physician, who is able to comply with the requirements that are stated in this document, may request information about how to apply for access to Xynomic investigational products by contacting the Company.
Any use of a Xynomic investigational product outside a clinical study in a country must be in accordance with local laws and regulations governing such programs, including Xynomic policies and procedures.

Available Therapies via Single-Patient EA

Abexinostat tablets for treatment of advanced renal cell carcinoma in combination with pazopanib. Xynomic will only provide abexinostat tablets.

Displaying 2 companies